chemotherapy/neoplasms

1. BACKGROUND OF THE INVENTION This invention relates in part to the use of RNA interference (RNAi) technology in cancer cells to knock out genes encoding DNA replication proteins, resulting in cell cycle arrest, and cytotoxicity. RNAi technology enables specific suppression of the expression of

FIELD OF THE INVENTION The present invention relates to improved treatment of cancer in animals, including humans, by reducing the side effects of chemotherapy. BACKGROUND OF THE INVENTION Cancers are a leading cause of death in animals and humans. The leading cancer therapies today are surgery,

CROSS REFERENCE TO RELATED APPLICATION This application is a national stage of international application No. PCT/JP2009/050020 filed on Jan. 6, 2009, which also claims priority under 35 USC 119 to Japanese Patent Application No. 2008-001801 filed Jan. 9, 2008, the entire content of which are

CROSS-REFERENCE TO RELATED APPLICATION This application claims priority benefits under 35 U.S.C. .sctn.119(e) to U.S. provisional application Ser. No. 61/668,077 filed Jul. 5, 2012, the entire content of which is incorporated by reference herein. BACKGROUND This invention relates generally to the

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to the use of ascorbic acid in combination with chemotherapeutic drugs to increase the inhibitory effects of the chemotherapy and to reduce its serious side effects and the use of ascorbic acid for radioprotection in

BACKGROUND 1. Technical Field This document relates to methods and materials involved in assessing chemotherapy responsiveness and treating cancer (e.g., breast cancer). For example, this document provides methods and materials for determining whether or not a cancer patient (e.g., a breast cancer

BACKGROUND Technical Field This disclosure relates to the field of chemotherapy treatment of patients having neoplastic disease. In particular, this disclosure relates to chemotherapy employing halogenated analogs of thymidine (abbreviated "HAT"). Background Information A. Pain Cancer-related pain,

CROSS REFERENCE TO RELATED APPLICATION The present application is a 35 U.S.C. .sctn.371 National Phase Entry Application from PCT/JP2012/062423, filed May 15, 2012, designating the United States, which in turn claims priority to Japanese Patent Application No. 2011-109599, filed on May 16, 2011,

FIELD OF THE INVENTION The present invention relates to the use of camptothecin derivatives as anti-cancer drugs. More specifically, the present invention is related to the use of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin, for the treatment of subjects with

BACKGROUND OF THE INVENTION 1. Field of Invention Cisplatin (cis-dichlorodiammine platinum II) is one of the more effective drugs used in cancer chemotherapy; however, the resulting violent emesis interferes with acceptance of therapy by the patient. This invention relates to an improvement in the

The present invention is directed to the use of a class of peptide compounds for treating tumor pain, in particular bone cancer pain, for treating chemotherapy-induced pain and for treating nucleoside-induced pain. Certain peptides are known to exhibit central nervous system (CNS) activity and are

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention is the use of known oxazolidinones to treat psoriasis, arthritis and to reduce the toxicity of cancer chemotherapy. 2. Description of the Related Art U.S. Pat. Nos. 5,164,510, 5,231,188, 5,565,571, 5,652,238 and 5,688,792

BACKGROUND OF THE INVENTION At the present time the progress of chemical attack on neoplasms is hindered by the inability of the therapist to deliver the cytotoxic dose to the tumor without exerting deleterious side effects such as nausea, leukepenia, thromocytopenia, diarrhea, alopecia, cirrhosis,

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a U.S. national stage filing of International Patent Application No. PCT/MX2005/00106 filed on Nov. 16, 2008. FIELD OF THE DISCLOSURE The use of transcriptome-modifying agents is disclosed to assist in the treatment of malignancies by

TECHNICAL FIELD This invention relates to cell transfection, and in particular methods of using adenoviral vectors for the suppression of tumor growth in conjunction with chemotherapy, radiation therapy or combinations thereof. BACKGROUND ART Neoplasia, also known as cancer, is the second most